40 results about "CSF Receptors" patented technology

The present invention provides compositions and methods that enhance cell survival. Such compositions feature chimeric polypeptides that include at least a GM-CSF receptor ligand and an anti-apoptotic moiety (e.g., a Bcl-2 protein family member). In one embodiment, the chimeric polypeptide is a GM-CSF-Bcl-xL chimeric polypeptide. The invention further includes methods of using chimeric polypeptides to enhance cell survival or inhibit cell death in a cell at risk of cell death.

In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and / or eCD8+ cDCs in the prevention and / or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and / or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and / or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and / or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.

A method of inducing the differentiation of ES cells into myocardial cells which comprises bringing the ES cells into contact with a G-CSF receptor agonist.

The present invention relates to the discovery that granulocyte colony stimulating factor (G-CSF) as well as granulocyte colony stimulating factor receptor (G-CSFR) are highly expressed in cancer tissue and the inhibition of G-CSF using a G-CSF inhibitor, which term includes inhibitors of the G-CSF receptor, represents a viable approach to the treatment of cancer, including drug resistant cancers, metastatic cancers and recurrent cancers. G-CSF inhibitors as described herein may be used alone or in combination with an at least one additional anti-cancer agent for the treatment of cancer.

The present invention relates generally to a method for the treatment and / or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.

In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and / or eCD8+ cDCs in the prevention and / or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and / or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and / or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and / or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.

Described herein are compound for the modulation of the G-CSF receptor. The compounds may act as agonists, antagonists, and / or mixed or partial agonists / antagonists of G-CSF. Further provided herein are methods of treating a condition, including, for example, a neurodegenerative disease, by administering a compound as detailed herein.

Antisense oligonucleotides for treating and / or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.

Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease.

Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and / or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.

The purpose of the present invention is to provide a humanized mouse that enables the long-term survival of human hematopoietic stem cells. The present invention is a humanized rodent in which human neutrophils circulate peripherally, and is obtained by transplanting human hematopoietic cells into a human G-CSF gene knocked-in rodent that expresses human G-CSF and does not express rodent G-CSF receptor. The human G-CSF gene knocked-in rodent is an immunodeficient rodent in which a human G-CSF gene has been knocked into the G-CSF receptor gene locus and the function of the G-CSF receptor has been lost.

The invention relates to methods and compositions comprising a macrophage colony stimulating factor (M-CSF) polypeptide or an agonist of the M-CSF receptor for preventing or treating myeloid cytopenia and related complications (such as infections) in a patient in need thereof (such as a patient undergoing hematopoietic stem cell transplantation).

The invention provides a granulocyte-macrophage colony stimulating factor antibody and application thereof, and belongs to the technical field of biological medicine. A granulocyte-macrophage colony stimulating factor (GM-CSF) antibody or fragment has high affinity, can effectively block GM-CSF / GM-CSF receptor interaction, and has low immunogenicity. The GM-CSF antibody or fragment can be used for preventing and / or treating diseases caused by human GM-CSF or detecting human GM-CSF protein or diagnosing related diseases caused by the human GM-CSF protein.

Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease.

The present application provides compositions and methods for producing antigen presenting cells (APCs) from cancer cells (e.g., hematological cancer cells) that involve one or more agents selected from a STAT3 activator (e.g., IL-10), IFNγ receptor activator (e.g., IFNγ ), TNFα receptor activator (e.g., TNFα), IL-4 receptor activator (e.g., IL-4), GM-CSF receptor activator (e.g., GM-CSF), and / or IL-6 receptor activator (e.g., IL-6). APCs produced accordingly are also provided, as well as methods of activating immune cells (e.g., T cells) via co-culturing with APCs. The activated immune cell compositions and the methods of treatments that involve the activated immune cells are also provided.

The present invention relates to methods for the treatment and / or prophylaxis of multiple sclerosis (MS). Antagonists of GM-CSF, such as antibodies specific for GM-CSF or the GM-CSF receptor, are effective in the treatment and / or prophylaxis of multiple sclerosis.

The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.

An objective of the present invention is to provide therapeutic agents for MLL leukemia and MOZ leukemia, which include an M-CSF receptor inhibitor as an active ingredient. Another objective of the present invention is to provide methods of screening for pharmaceutical compositions that treat or prevent leukemia by suppressing the expression or activity of M-CSF receptor. Still another objective of the present invention is to provide methods of testing for leukemia, which include the step of determining the expression level of an M-CSF receptor. The present inventors conducted dedicated studies, and as a result revealed that the M-CSF receptor (M-CSFR, CSF1R, c-FMS, or CD115) is highly expressed in cells having the activity of inducing MLL or MOZ leukemia (leukemia stem cells), both of which are intractable acute leukemia. Specifically, the present inventors discovered that the M-CSF receptor signal is closely associated with the leukemia onset.

The invention provides an application of an IL-4 receptor activator or an M-CSF receptor activator in enhancing mRNA editing macrophage efficiency, and relates to the technical field of biology. IL-4 is an activator of the IL-4 receptor, and M-CSF is an activator of the M-CSF receptor. The research of the inventor finds that IL-4, M-CSF or the lipid nanoparticles loaded with mRNA thereof can significantly improve the in-vivo and in-vitro editing efficiency of the lipid nanoparticles loaded with target mRNA on macrophages. Wherein the effect of the M-CSF is better, and the M-CSF plays an important role in the differentiation, maturation and proliferation processes of the macrophages, so that the M-CSF can obviously improve the editing efficiency of an LNP-mRNA system on the macrophages on the basis of improving the functions of the macrophages; therefore, the application value of in-vivo editing of macrophages by using the LNP-mRNA system in the field of various diseases in the future is greatly expanded.

Described herein is the use of non-agonist ligands, in particular antibodies, that specifically bind to GM-CSF or to one of the GM-CSF receptors consisting of CD116, CD131 and CD131, for treating leukemia in patients who have received allo-HCT or for treating other complications arising from hematopoietic cell transplantation from immunologically different donors.

The present invention provides compositions and methods for generating antigen presenting cells (APCs) from monocytes (e.g., monocytes from cancer patients) that relate to IL-10 receptor activators (e.g., IL-10), IFN gamma receptor activators (e.g., IFN gamma), TNF alpha receptor activators (e.g., TNF alpha), IL-4 receptor activators (e.g., IL-4), GM-CSF receptor activators (e.g., GM-CSF receptor activators). E.g., GM-CSF (e.g., GM-CSF) and / or an IL-6 receptor activator (e.g., IL-6). Also provided are APCs thus produced, as well as methods of activating immune cells (e.g., T cells) by co-culture with APCs. Also provided are activated immune cell compositions and methods of treatment involving activated immune cells.

The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present invention are used for treating and / or preventing asthma, allergy, hypereosinophilia, general inflammation or cancer. The oligonucleotides of the present invention are more specifically directed against nucleic acid sequences coding for a CCR3 receptor, a common sub-unit of IL-4 and IL-13 receptors, or a common sub-unit of IL-3, IL-5 and GM-CSF receptors.